0013407 2023 RIV GB eng J
Salmon, M. - White, H.E. - Žižková, Hana - Gottschalk, A. - Motlová, Eliška - Cerveira, N. - Colomer, D. - Coriu, D. - Franke, G.N. - Gottardi, E. - Izzo, B. - Jurček, T. - Lion, T. - Schäfer, V. - Venturi, C. - Vigneri, P. - Zawada, M. - Zuna, J. - Hovorková, L. - Koblihová, Jitka - Klamová, Hana - Šťastná Marková, Markéta - Srbová, Dana - Benešová, Adéla - Polívková, Václava - Žáčková, D. - Mayer, J. - Roeder, I. - Glauche, I. - Ernst, T. - Hochhaus, A. - Machová Poláková, Kateřina - Cross, N.C.P.
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Leukemia. Vol. 36, no. 7 (2022), s. 1879-1886. ISSN 0887-6924
Institucionální podpora: RVO:00023736
Klíčová slova: BCR::ABL1 transcript * qRT-PCR * CML * EUTOS
Cite Score: 17.100, rok: 2022; SJR: 3.376, rok: 2022; IF: 11.4, rok: 2022
DOI: 10.1038/s41375-022-01612-2

Anotace: Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. To explore the reason for this difference we undertook a detailed technical comparison of the commonly used Europe Against Cancer (EAC) BCR::ABL1 reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assay in European Treatment and Outcome Study (EUTOS) reference laboratories (n = 10).